Targeting osteosarcoma, a cancer more common in young people

Knight Cancer researchers describe positive results with the drug regorafenib. Osteosarcoma is a bone cancer that disproportionately affects teenagers, and despite substantial efforts, outcomes for...

Top papers in prostate cancer co-authored by OHSU faculty

Physician-scientists with the OHSU Knight Cancer Institute co-authored three of the 25 most important prostate cancer studies published this year, and one runner up, as judged by the Prostate Cancer...

Acclaim for a precision oncology pioneer in Oregon

Like few other drugs in the history of oncology, Gleevec transformed the outlook for patients: a disease with a life expectancy of less than five years – chronic myeloid leukemia – became a...

Cracking the code of advanced prostate cancer

Understanding the tumor-specific alterations that are most important for prostate cancer aggressiveness and treatment decision-making will be the focus of a Marquam Hill...

A new line of attack on deadly prostate cancers

Researchers have uncovered a potential drug target for stopping castration-resistant prostate tumors – the second leading cause of cancer death in the U.S. For decades, drug development for...